Brand X has been extensively studied in major clinical trials demonstrating significant blood pressure lowering and a favorable safety profile. Review the pivotal trial data.
HYPERTrial
Randomized, double-blind study in 1,512 patients with stage 1-2 hypertension. Brand X reduced systolic BP an average of 12 mmHg more than placebo after 12 weeks.
BpCompare Study
Compared Brand X to amlodipine for efficacy and safety in 806 patients over 6 months. Brand X was non-inferior in mean BP reduction with fewer side effects.
LongTerm-HTN Study
5-year open-label follow-up study of 785 patients on long-term Brand X therapy. Maintained sustained BP control throughout with no new safety signals.
Pediatric Trial in Hypertension
16-week safety and efficacy trial of Brand X in children ages 6-17 with primary hypertension. Achieved significant BP lowering comparable to adults.
RESIST-HTN Study
Randomized, double-blind study in 671 patients with resistant hypertension uncontrolled on 3 agents. Adding Brand X lowered systolic BP an extra 13 mmHg versus placebo after 12 weeks of treatment.
SAGE-HTN trial
The SAGE-HTN trial provides robust evidence demonstrating Brand X is effective for lowering blood pressure in elderly patients ≥65 years old with hypertension, to a similar degree as observed in younger adult studied populations.
The REINFORCE trial
The REINFORCE trial demonstrated Brand X treatment effectively preserved kidney function and improved markers of renal damage like albuminuria versus standard of care alone in patients with hypertension complicated by moderate CKD.
The CAPTAIN trial
The CAPTAIN trial demonstrated Brand X led to fewer discontinuations and improved side effect profiles that may support better medication compliance versus older agent classes in stroke survivors requiring lifelong blood pressure management.
Brand X has proven efficacy for hypertensive patients through rigorous clinical evaluation in major studies. Review the data and publications.